Difference between revisions of "Performance Based Pricing"
From Patient Determinants
(Created page with "* [http://www.beckershospitalreview.com/finance/cigna-novartis-agree-on-outcome-based-price-for-heart-drug.html Cigna, Novartis agree on outcome-based price for heart drug (2/...") |
|||
(4 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
+ | * [https://www.beckershospitalreview.com/supply-chain/novartis-cms-collaborate-on-outcomes-based-pricing-for-465k-leukemia-drug.html Novartis, CMS collaborate on outcomes-based pricing for $475k leukemia drug (8/31/17)] | ||
+ | * [https://www.fiercehealthcare.com/analytics/patient-generated-data-could-be-missing-piece-to-new-payment-models-for-drugs-and-devices A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. (7/25/17)] | ||
+ | * [https://healthpayerintelligence.com/news/amp/harvard-pilgrim-enters-outcomes-based-pharmaceutical-contracts Harvard Pilgrim Health Care has expanded its outcomes-based care contracts for certain pharmaceuticals by using outcomes as a metric for drug costs. (6/2/17)] | ||
* [http://www.beckershospitalreview.com/finance/cigna-novartis-agree-on-outcome-based-price-for-heart-drug.html Cigna, Novartis agree on outcome-based price for heart drug (2/9/16)] | * [http://www.beckershospitalreview.com/finance/cigna-novartis-agree-on-outcome-based-price-for-heart-drug.html Cigna, Novartis agree on outcome-based price for heart drug (2/9/16)] | ||
* [http://www.beckershospitalreview.com/payer-issues/cigna-first-insurer-to-reach-value-based-agreements-for-new-class-of-cholesterol-drugs.html Cigna first insurer to reach value-based agreements for new class of cholesterol drugs (5/12/16)] | * [http://www.beckershospitalreview.com/payer-issues/cigna-first-insurer-to-reach-value-based-agreements-for-new-class-of-cholesterol-drugs.html Cigna first insurer to reach value-based agreements for new class of cholesterol drugs (5/12/16)] | ||
+ | |||
+ | See [http://www.patientdeterminants.org/index.php?title=Health_Insurance_Payment_Models#Performance_Based_Pricing Health Insurance Payment Models - Performance Based Pricing] |
Latest revision as of 14:05, 16 July 2019
- Novartis, CMS collaborate on outcomes-based pricing for $475k leukemia drug (8/31/17)
- A new consortium of payers, providers and manufacturers at the Duke Margolis Center for Health Policy aims to tackle the complex issue of value-based payment for drugs, medical devices and cutting-edge gene therapy. (7/25/17)
- Harvard Pilgrim Health Care has expanded its outcomes-based care contracts for certain pharmaceuticals by using outcomes as a metric for drug costs. (6/2/17)
- Cigna, Novartis agree on outcome-based price for heart drug (2/9/16)
- Cigna first insurer to reach value-based agreements for new class of cholesterol drugs (5/12/16)
See Health Insurance Payment Models - Performance Based Pricing